An Open-Label, Single Center, Nonrandomized, Phase 1 Study to Evaluate Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 13 Jun 2017 Status changed from not yet recruiting to recruiting.
- 25 Apr 2017 New trial record